|Articles|October 1, 2003

Timing issues are important when treating invasive TCC

Articles in this month's Urology Times deal with an issue of "timing"when determining the treatment of invasive transitional cell carcinoma ofthe bladder.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!

Latest CME

Video

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Arizona

Surabhi Amar, MD, MHA, MBBS; Scott T. Tagawa, MD, MS, FACP, FASCO

Video

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Scott T. Tagawa, MD, MS, FACP, FASCO; Kate Baxstrom, MD

In-Person Event

DSUI Urology on the Beach

January 16-18, 2026

Register now!

Video

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

Video

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Multimedia

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Video

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Multimedia

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Aaron D. Berger, MD

Multimedia

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Jason M. Hafron, MD

Multimedia

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Stacy Loeb, MD, MSc, PhD (Hon)

Timing issues are important when treating invasive TCC

Newsletter

Related Content

Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC

Cretostimogene demonstrates safety, efficacy in papillary NMIBC cohort

SYNC-T demonstrates high bone metastasis resolution in phase 1 cohort

CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBC

Gemcitabine intravesical system reduces recurrence, limits need for cystectomy

Latest CME

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Arizona

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

DSUI Urology on the Beach

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Radioligand Therapy 101: The Science Behind the Strategy

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Trending on Urology Times

Mark Tyson, MD shares promising BOND-003 results in papillary NMIBC

CORE-008: Cretostimogene achieves high CR rate in high-risk NMIBC

Gemcitabine intravesical system delivers high 12-month DFS in papillary-only NMIBC

Choosing salvage therapy after prostate cancer focal ablation

NDV-01 produces robust 9-month results in high-risk NMIBC